Lung Pathology: Lung Pathology |

Serum Amyloid a in Patients With Sarcoidosis FREE TO VIEW

Barbara Salobir, PhD; Zala Lestan, MD; Snezna Sodin; Katja Lakota; Marjeta Tercelj, PhD
Author and Funding Information

University Medical Centre, Medical Faculty, Ljubljana, Slovenia

Copyright 2016, American College of Chest Physicians. All Rights Reserved.

Chest. 2016;150(4_S):789A. doi:10.1016/j.chest.2016.08.885
Text Size: A A A
Published online

SESSION TITLE: Lung Pathology

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM

PURPOSE: A novel hypothesis proposes that serum amyloid A (SAA) within granulomas promotes sarcoidosis inflammation. Since presence of SAA in sarcoid granuloma and higher serum levels were found in patients requiring prolonged and multiple steroid treatments, the aim of our study was to test association between SAA and markers of inflammation and sarcoidosis extent in dependence of glucocorticoid treatment.

METHODS: SAA was measured (BN ProSpec System, Siemens AG, Munich, Germany) in a cross-sectional study of 125 sarcoidosis patients. Associations were calculated between SAA and high sensitivity CRP, procalcitonine (PCT), angiotensin-converting-enzyme (ACE), chitotriosidase (CTO), pulmonary lung function, extent of mediastinal enlargement, lung granuloma infiltration and fibrosis, as estimated on a chest X-ray.

RESULTS: In the whole group SAA (median6.4, min6.4-max181) correlated only with CRP (r=0.556, p<0.000), PCT (r=0.26, p<0.05) and enlargement of lymph nodes (r=0.21, p<0,01). SAA in a subgroup treated with corticosteroids (n=30, median8.7, min6.4-max181) was higher (p=0.004) than in not-treated group (N=95, median6.4, min6.4-max61.7) and correlated with CRP (r=0.364, p<0.05), PCT (r=0.26, p<0.05), extent of mediastinal lymph node enlargement (r=0.372, p=0.056), lung granuloma infiltration (r=0.355, p=0.064) pulmonary fibrosis (r=0.526, p<0.005) and DLCO (r=-0.445, p<0.05). No significant correlations were found with ACE or CTO.

CONCLUSIONS: SAA provided significant correlation in the corticosteroid treated group with CRP and clinical features of lung damage but not markers of sarcoidosis activity thus SAA might be a marker of sarcoidosis patients unresponsive to glucocorticoid therapy.

CLINICAL IMPLICATIONS: SAA might be a marker of sarcoidosis patients unresponsive to glucocorticoid therapy, what have to be proved in further studies.

DISCLOSURE: The following authors have nothing to disclose: Barbara Salobir, Zala Lestan, Snezna Sodin, Katja Lakota, Marjeta Tercelj

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543